A Clinical Study of Standard TEMODAL [temozolomide] Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).
Latest Information Update: 10 May 2022
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 31 May 2013 Primary endpoint 'Overall-survival-duration' has been met.
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 03 Oct 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.